GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medipharm Labs LABS.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

0.06

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Revenue

C$45.1m

FY2016FY2025

Net income

−C$8.3m

FY2016FY2025

Free cash flow

−C$5.6m

FY2016FY2025

Shareholders' equity

C$35.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueC$45.1mC$42.0mC$33.1mC$22.1mC$21.7mC$36.0mC$129.3m———
Research and developmentC$223,000C$235,000C$209,000C$1.0mC$1.4mC$2.2mC$867,000———
Operating income−C$8.4m−C$10.8m−C$18.3m−C$29.5m−C$44.4m−C$72.6mC$6.9m−C$213,538−C$948,000−C$133,936
Net income−C$8.3m−C$10.7m−C$13.1m−C$30.0m−C$54.8m−C$67.1mC$1.1m−C$211,103−C$990,000−C$133,936
Diluted earnings per share-0.02-0.03-0.03-0.11-0.22-0.490.01-0.00-0.20-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsC$45.7mC$53.7mC$63.9mC$65.5mC$92.4mC$118.2mC$168.8m—C$400,000C$262,185
Cash and short-term investmentsC$10.8mC$11.7mC$18.0mC$24.1mC$34.1mC$19.9mC$38.6m—C$400,000C$262,185
Total liabilitiesC$9.9mC$10.5mC$10.9mC$9.5mC$9.2mC$39.8mC$37.6m—C$2.5mC$46,726
DebtC$201,000C$388,000C$2.3mC$632,000C$216,000C$18.5mC$10.6m—C$1.2mC$24,862
Shareholders' equityC$35.8mC$43.2mC$53.0mC$56.0mC$83.1mC$78.4mC$131.5m—C$400,000C$215,459
Shares outstanding421m408m401m282m249m136m136m98m5m426m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−C$5.5m−C$4.9m−C$12.3m−C$16.1m−C$13.2m−C$37.8m−C$25.3m−C$102,140C$166,000−C$54,692
Capital spending−C$100,000−C$154,000−C$471,000−C$863,000−C$783,000−C$7.5m−C$32.4m—−C$2.1m−C$2.1m
Free cash flow−C$5.6m−C$5.0m−C$12.8m−C$16.9m−C$14.0m−C$45.3m−C$57.7m−C$102,140−C$2.0m−C$2.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueC$10.0mC$9.0mC$11.1mC$11.4mC$11.8mC$10.8mC$12.0mC$9.8m
Operating income−C$163,000−C$848,000−C$2.0m−C$2.2m−C$3.8m−C$441,000−C$1.9m−C$2.7m
Net incomeC$4,000−C$867,000−C$2.0m−C$2.1m−C$3.8m−C$387,000−C$1.7m−C$2.8m
Diluted earnings per share0.00-0.00-0.00-0.01-0.01-0.00-0.00-0.01
Cash from operations————−C$2.0m−C$3.0m−C$1.0m—
Total assetsC$46.0mC$43.6mC$45.7mC$46.6mC$49.3mC$52.1mC$53.7mC$55.8m
Cash and short-term investmentsC$9.8mC$9.9mC$10.8mC$10.6mC$10.4mC$8.4mC$11.7mC$13.1m
DebtC$421,000C$18,000C$201,000C$423,000C$542,000C$125,000C$388,000C$654,000
Shareholders' equityC$35.4mC$35.1mC$35.8mC$37.9mC$39.8mC$43.2mC$43.2mC$45.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue26.8%4.6%—
Operating income-34.2%-35.0%—
Net income-34.9%-34.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-3.3-2.3-2.0-0.7-0.8-1.1464.2-804.0
Price to sales0.60.60.80.92.12.04.1—

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-to-1 reverse split · 4 Oct 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.